Literature DB >> 11453888

Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis.

J A Webb1, A Rostami-Hodjegan, R Abdul-Manap, U Hofmann, G Mikus, F Kamali.   

Abstract

AIMS: It is not clear whether the analgesic effect following dihydrocodeine (DHC) administration is due to either DHC itself or its metabolite, dihydromorphine (DHM). We examined the relative contribution of DHC and DHM to analgesia following DHC administration in a group of healthy volunteers using a PK-PD link modelling approach.
METHODS: A single oral dose of DHC (90 mg) was administered to 10 healthy volunteers in a randomised, double-blind, placebo-controlled study. A computerized cold pressor test (CPT) was used to measure analgesia. On each study day, the volunteers performed the CPT before study medication and at 1.25, 2.75, 4.25 and 5.75 h postdose. Blood samples were taken at 0.25 h (predose) and then at half hourly intervals for 5.75 h postdose. PK-PD link modelling was used to describe the relationships between DHC, DHM and analgesic effect.
RESULTS: Mean pain AUCs following DHC administration were significantly different to those following placebo administration (P = 0.001). Mean pain AUC changes were 91 score x s(-1) for DHC and -17 score x s(-1) for placebo (95% CI = +/- 36.5 for both treatments). The assumption of a simple linear relationship between DHC concentration and effect provided a significantly better fit than the model containing DHM as the active moiety (AIC = 4.431 vs 4.668, respectively). The more complex models did not improve the likelihood of model fits significantly.
CONCLUSIONS: The findings suggest that the analgesic effect following DHC ingestion is mainly attributed to the parent drug rather than its DHM metabolite. It can thus be inferred that polymorphic differences in DHC metabolism to DHM have little or no effect on the analgesic affect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453888      PMCID: PMC2014498          DOI: 10.1046/j.0306-5251.2001.01414.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine.

Authors:  N D Evans; K R Godfrey; M J Chapman; M J Chappell; L Aarons; S B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

2.  Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam.

Authors:  B Tuk; M F van Oostenbruggen; V M Herben; J W Mandema; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1999-05       Impact factor: 4.030

3.  Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers.

Authors:  S B Duffull; L Aarons
Journal:  Eur J Pharm Sci       Date:  2000       Impact factor: 4.384

4.  Receptor binding and pharmacological activity of opiates in the guinea-pig intestine.

Authors:  I Creese; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1975-07       Impact factor: 4.030

Review 5.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

Authors:  M Eichelbaum; A S Gross
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

6.  Treatment of depression with E-10-hydroxynortriptyline--a pilot study on biochemical effects and pharmacokinetics.

Authors:  C Nordin; L Bertilsson; M L Dahl; B Resul; G Toresson; F Sjöqvist
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

7.  Effects of an opiate on cold-induced pain and the CNS in healthy volunteers.

Authors:  John Posner; Andras Telekes; Dominic Crowley; Richard Phillipson; Anthony W Peck
Journal:  Pain       Date:  1985-09       Impact factor: 6.961

8.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

9.  The antitussive effect of dextromethorphan in relation to CYP2D6 activity.

Authors:  R Abdul Manap; C E Wright; A Gregory; A Rostami-Hodjegan; S T Meller; G R Kelm; M S Lennard; G T Tucker; A H Morice
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

10.  Analgesic efficacy of controlled-release dihydrocodeine. A comparison of 60, 90 and 120 mg tablets in cold-induced pain.

Authors:  H A Wotherspoon; G N Kenny; C S McArdle
Journal:  Anaesthesia       Date:  1991-11       Impact factor: 6.955

View more
  7 in total

Review 1.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

2.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

3.  Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans.

Authors:  Helmut Schmidt; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2007-09-05       Impact factor: 2.953

4.  Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study.

Authors:  B Frank; M G Serpell; J Hughes; J N S Matthews; D Kapur
Journal:  BMJ       Date:  2008-01-08

Review 5.  Pain management in patients with cancer: focus on opioid analgesics.

Authors:  Wojciech Leppert
Journal:  Curr Pain Headache Rep       Date:  2011-08

6.  Pharmacogenomic considerations in opioid analgesia.

Authors:  Pascal H Vuilleumier; Ulrike M Stamer; Ruth Landau
Journal:  Pharmgenomics Pers Med       Date:  2012-08-23

7.  Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders.

Authors:  Tara Carney; Marie Claire Van Hout; Ian Norman; Siphokazi Dada; Nandi Siegfried; Charles Dh Parry
Journal:  Cochrane Database Syst Rev       Date:  2020-02-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.